Zongertinib Delivers 76% Response Rate as a First-Line Therapy in HER2-Mutant NSCLC

Results from the phase 1b Beamion LUNG-1 trial (NCT04886804), published in The New England Journal of Medicine, show that zongertinib (Hernexeos; Boehringer Ingelheim) delivered durable responses as a first-line therapy in patients with HER2-mutant advanced non–small cell lung cancer (NSCLC)—a population that has historically had few targeted options.¹

Filling a First-Line Gap

HER2 mutations drive up to 4% of lung cancers, yet until recently no first-line targeted therapy was available for this patient population. Zongertinib is an oral, irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing wild-type epidermal growth factor receptor (EGFR)—a design intended to preserve efficacy while reducing the EGFR-related toxicities that have limited other agents in this class.²

The drug received FDA accelerated approval for previously treated patients with HER2-mutant advanced NSCLC in August 2025. The newly published data, presented at the European Lung Cancer Congress in Copenhagen, extend those findings to the first-line setting.²

Regarding the Results

The primary analysis included 74 previously untreated patients with advanced or metastatic nonsquamous HER2-mutant NSCLC who received zongertinib 120 mg once daily (cohort 2). As of the August 21, 2025, data cutoff, the confirmed objective response rate was 76% (95% CI, 65–84), with 11% of patients achieving a complete response and 65% a partial response.²

Durability was a particular highlight. The median duration of response was about 15.2 months (95% CI, 9.8–not evaluable [NE]), and the median progression-free survival was 14.4 months (95% CI, 11.1–NE).^1,2

The trial also evaluated zongertinib in 30 patients with active brain metastases (exploratory cohort 4), a notoriously difficult-to-treat population. Nearly half of patients (47% [95% CI, 30–64]) achieved a confirmed intracranial objective response per RANO-BM criteria, suggesting meaningful central nervous system activity.^1,2

Reviewing the Safety Profile

Treatment-related adverse events (TRAEs) occurred in 91% of patients, though the majority were low-grade. Grade 3 or higher TRAEs were reported in approximately 19% of patients in cohort 2 and 17% in cohort 4. AEs led to dose reductions in 16% of patients and discontinuations in 9%. No new safety signals emerged.²

Regulatory and Clinical Context

In early 2026, the FDA granted zongertinib accelerated approval for treatment-naïve patients with unresectable or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test—building on its prior accelerated approval in the previously treated setting. Confirmatory data are being generated in the ongoing phase 3 Beamion LUNG-2 trial (NCT06151574), which is evaluating zongertinib as first-line therapy in this population.

“This data shows zongertinib demonstrated durable efficacy as first-line therapy in treatment-naïve patients with HER2-mutant advanced NSCLC, a setting where there are currently limited options with durable responses,” said coordinating investigator for the Beamion LUNG-1 trial John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. “These findings, now published in The New England Journal of Medicine, may help health care providers make informed decisions on HER2 targeted treatment choices.”

REFERENCES

1. Heymach JV, Yamamoto N, Girard N, et al. First-line zongertinib in advanced HER2-mutant non–small-cell lung cancer. N Engl J Med. April 15, 2026. doi:10.1056/NEJMoa2516969

2. Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine. Boehringer Ingelheim. April 16, 2026. Accessed May 13, 2026. https://www.boehringer-ingelheim.com/us/human-health/cancer/lung-cancer/nejm-publishes-results-patients-her2-mutant-nsclc?cid=linkedin:social_organic:AW:nejmsocial